Sionna Therapeutics, Inc. Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- Sionna Therapeutics, Inc. price/book ratio for the quarter ending 2026-06-30 was 7.47, a 227.16% increase year-over-year.
- Sionna Therapeutics, Inc. price/book ratio for the quarter ending 2026-03-31 was 6.26, a 377.63% increase year-over-year.
- Sionna Therapeutics, Inc. price/book ratio for the quarter ending 2025-12-31 was 6.01.
- Sionna Therapeutics, Inc. price/book ratio for the quarter ending 2025-09-30 was 4.07.
- Sionna Therapeutics, Inc. price/book ratio for fiscal 2026 was 7.47.
- Sionna Therapeutics, Inc. price/book ratio for fiscal 2025 was 6.01.
- Available history
- 2025-03-31 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |